Kyowa Kirin (KYKOF) Stock Price, News & Analysis

Company Overview

Kyowa Kirin Co., Ltd. is a Japan-based specialty pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company focuses on therapies for areas including oncology, immunology, nephrology, the central nervous system and rare diseases, with an emphasis on biologics and other innovative treatments.

Its products include Poteligeo (mogamulizumab), an antibody used in certain hematologic cancers and cutaneous T-cell lymphomas, and Crysvita (burosumab), a treatment for disorders involving abnormal phosphate regulation. Kyowa Kirin also develops medicines for patients with serious or underserved conditions and maintains research programs spanning multiple therapeutic fields.

The company serves patients and healthcare providers in Japan and international markets, including North America, Europe and other regions of Asia. Kyowa Kirin traces its history to Japan’s Kyowa Hakko pharmaceutical business and its combination with Kirin Pharma. It operated as Kyowa Hakko Kirin before adopting the Kyowa Kirin name in 2019 and is part of the Kirin Holdings group.

Key Stats

• Today's Range: $13.14 to $14.30
• 50-Day Range: $13.90 to $15.80
• 52-Week Range: $4.20 to $15.90
• Volume: 1,000 shs
• Average Volume: 20,826 shs
• Market Capitalization: N/A
• P/E Ratio: 0.42
• Dividend Yield: 139.44%
• Price Target: N/A
• Consensus Rating: Reduce

Kyowa Kirin Stock Analysis - MarketRank™

Kyowa Kirin scored higher than 23% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Kyowa Kirin has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Kyowa Kirin has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Kyowa Kirin is 0.38, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.86.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kyowa Kirin is 0.38, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.56.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Kyowa Kirin has a short interest ratio ("days to cover") of 31.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Kyowa Kirin has recently decreased by 56.48%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Kyowa Kirin pays a meaningful dividend of 1.56%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Kyowa Kirin does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Kyowa Kirin is 58.08%. This payout ratio is at a healthy, sustainable level, below 75%.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: N/A

News Sentiment

Kyowa Kirin has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Kyowa Kirin this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kyowa Kirin insiders have not sold or bought any company stock.

Percentage Held by Institutions

10.28% of the stock of Kyowa Kirin is held by institutions.

Company Calendar

• Today: 10/13/2026
• Next Earnings (Estimated): 11/02/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:KYKOF
• CIK: N/A
• Web: www.kyowakirin.com
• Phone: (135) 205-7200
• Fax: N/A
• Employees: 5,974
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 0.42
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A